全文获取类型
收费全文 | 3376篇 |
免费 | 230篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 130篇 |
妇产科学 | 94篇 |
基础医学 | 538篇 |
口腔科学 | 36篇 |
临床医学 | 275篇 |
内科学 | 769篇 |
皮肤病学 | 80篇 |
神经病学 | 499篇 |
特种医学 | 86篇 |
外科学 | 316篇 |
综合类 | 13篇 |
一般理论 | 1篇 |
预防医学 | 206篇 |
眼科学 | 24篇 |
药学 | 224篇 |
中国医学 | 5篇 |
肿瘤学 | 305篇 |
出版年
2024年 | 6篇 |
2023年 | 45篇 |
2022年 | 114篇 |
2021年 | 147篇 |
2020年 | 100篇 |
2019年 | 124篇 |
2018年 | 115篇 |
2017年 | 98篇 |
2016年 | 108篇 |
2015年 | 126篇 |
2014年 | 171篇 |
2013年 | 189篇 |
2012年 | 307篇 |
2011年 | 298篇 |
2010年 | 149篇 |
2009年 | 137篇 |
2008年 | 252篇 |
2007年 | 203篇 |
2006年 | 167篇 |
2005年 | 181篇 |
2004年 | 143篇 |
2003年 | 119篇 |
2002年 | 86篇 |
2001年 | 21篇 |
2000年 | 20篇 |
1999年 | 19篇 |
1998年 | 18篇 |
1997年 | 16篇 |
1996年 | 16篇 |
1995年 | 4篇 |
1994年 | 9篇 |
1993年 | 13篇 |
1992年 | 13篇 |
1991年 | 13篇 |
1990年 | 9篇 |
1989年 | 3篇 |
1988年 | 10篇 |
1987年 | 11篇 |
1986年 | 13篇 |
1985年 | 4篇 |
1984年 | 7篇 |
1983年 | 2篇 |
1980年 | 3篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1967年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有3621条查询结果,搜索用时 15 毫秒
91.
92.
Marco Ugo Andrea Sartorio Erica Pendezza Serena Coppola Lorella Paparo Enza DAuria Gian Vincenzo Zuccotti Roberto Berni Canani 《Nutrients》2022,14(1)
Polyunsaturated fatty acids (PUFAs) are involved both in immune system regulation and inflammation. In particular, within the PUFAs category, omega-3 (ω-3) may reduce inflammation, whereas omega-6 (ω-6) PUFAs are generally considered to have a proinflammatory effect. Recent evidence highlights an imbalance in the ω-3:ω-6 ratio with an increased intake of ω-6, as a consequence of the shift towards a westernized diet. In critical age groups such as infants, toddlers and young children, as well as pregnant and lactating women or fish allergic patients, ω-3 intake may be inadequate. This review aims to discuss the potential beneficial effects of PUFAs on pediatric food allergy prevention and treatment, both at prenatal and postnatal ages. Data from preclinical studies with PUFAs supplementation show encouraging effects in suppressing allergic response. Clinical studies results are still conflicting about the best timing and dosages of supplementation and which individuals are most likely to benefit; therefore, it is still not possible to draw firm conclusions. With regard to food-allergic children, it is still debated whether PUFAs could slow disease progression or not, since consistent data are lacking. In conclusion, more data on the effects of ω-3 PUFAs supplementation alone or in combination with other nutrients are warranted, both in the general and food allergic population. 相似文献
93.
Bernardo Patella Nadia Moukri Gaia Regalbuto Chiara Cipollina Elisabetta Pace Serena Di Vincenzo Giuseppe Aiello Alan ORiordan Rosalinda Inguanta 《Materials》2022,15(3)
Immunoglobulin G (IgG), a type of antibody, represents approximately 75% of serum antibodies in humans, and is the most common type of antibody found in blood circulation. Consequently, the development of simple, fast and reliable systems for IgG detection, which can be achieved using electrochemical sandwich-type immunosensors, is of considerable interest. In this study we have developed an immunosensor for human (H)-IgG using an inexpensive and very simple fabrication method based on ZnO nanorods (NRs) obtained through the electrodeposition of ZnO. The ZnO NRs were treated by electrodepositing a layer of reduced graphene oxide (rGO) to ensure an easy immobilization of the antibodies. On Indium Tin Oxide supported on Polyethylene Terephthalate/ZnO NRs/rGO substrate, the sandwich configuration of the immunosensor was built through different incubation steps, which were all optimized. The immunosensor is electrochemically active thanks to the presence of gold nanoparticles tagging the secondary antibody. The immunosensor was used to measure the current density of the hydrogen development reaction which is indirectly linked to the concentration of H-IgG. In this way the calibration curve was constructed obtaining a logarithmic linear range of 10–1000 ng/mL with a detection limit of few ng/mL and good sensitivity. 相似文献
94.
Cataldo Patruno Luca Stingeni Katharina Hansel Silvia Mariel Ferrucci Simona Tavecchio Gabriella Fabbrocini Steven Paul Nistic Caterina Foti Serena De Prezzo Maddalena Napolitano 《Dermatologic therapy》2020,33(3)
Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular‐like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)‐4 and IL‐13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult. 相似文献
95.
Morassi Mauro Bagatto Daniele Cobelli Milena D’Agostini Serena Gigli Gian Luigi Bnà Claudio Vogrig Alberto 《Journal of neurology》2020,267(8):2185-2192
Journal of Neurology - Italy is one of the most affected countries by the coronavirus disease 2019 (COVID-19). The responsible pathogen is named severe acute respiratory syndrome coronavirus... 相似文献
96.
Sanne C. F. A. Huijberts Robin M. J. M. van Geel Emilie M. J. van Brummelen Frans L. Opdam Serena Marchetti Neeltje Steeghs Saskia Pulleman Bas Thijssen Hilde Rosing Kim Monkhorst Alwin D. R. Huitema Jos H. Beijnen Ren Bernards Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2020,85(5):917-930
KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were treated with combined lapatinib and trametinib to assess the recommended phase 2 regimen (RP2R). Patients received escalating doses of continuous or intermittent once daily (QD) orally administered lapatinib and trametinib, starting at 750 mg and 1 mg continuously, respectively. Thirty-four patients (16 CRC, 15 NSCLC, three pancreatic cancers) were enrolled across six dose levels and eight patients experienced dose-limiting toxicities, including grade 3 diarrhea (n = 2), rash (n = 2), nausea (n = 1), multiple grade 2 toxicities (n = 1), and aspartate aminotransferase elevation (n = 1), resulting in the inability to receive 75% of planned doses (n = 2) or treatment delay (n = 2). The RP2R with continuous dosing was 750 mg lapatinib QD plus 1 mg trametinib QD and with intermittent dosing 750 mg lapatinib QD and trametinib 1.5 mg QD 5 days on/2 days off. Regression of target lesions was seen in 6 of the 24 patients evaluable for response, with one confirmed partial response in NSCLC. Pharmacokinetic results were as expected. Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated. 相似文献
97.
98.
Maura Massimino Michela Casanova Daniela Polastri Veronica Biassoni Piergiorgio Modena Emilia Pecori Elisabetta Schiavello Marco Vajna De Pava Alice Indini Paolo Rampini Dario Bauer Serena Catania Marta Podda Lorenza Gandola 《Child's nervous system》2013,29(7):1107-1112
Purpose
We retrospectively report strategies used for medulloblastoma patients progressing after craniospinal irradiation where we aimed for: symptom control, a satisfactory quality of life, accrual in phase 1–2 trials, when available, and the first two conditions could no longer be satisfied by already experienced second-line strategies.Methods
Surgery was used in cases of doubtful relapse or when only one site was affected. Radiotherapy was given whenever possible, especially to relieve symptoms. The main chemotherapy regimens were oral temozolomide/etoposide, intravenous (iv.) cisplatin/etoposide, iv. gemcitabine/oxaliplatin, an oral sonic hedgehog pathway inhibitor and oral melphalan.Results
Between 1998 and 2011, we treated 18 patients relapsed after median 20 months. Nine had relapsed locally, four had dissemination, three single metastases, and two had one synchronous local and metastatic recurrence. Responses to chemotherapy were seen in 32 % of cases. The median hospital stay for treatments/complications was 19 days. The 1- and 3-year progression-free survival (PFS) rates were 28?±?10 % and 0 %, respectively, for OS, they were 44?±?12 % and 22?±?10 % but no patient was cured. The median PFS after a first relapse was 7 months (range 1–29); the median OS was 7 months (range 4–44). No patients died due to treatment toxicity. Late recurrence (more than 1–2 years after diagnosis) and involvement of single sites were favorable prognostic factors.Conclusions
Without succeeding in patients cure, we ensured them further treatment with short hospital stay thus affording low personal and social costs. The chances of cure may emerge from tailored therapies according to genetic stratification. 相似文献99.
Michelangelo Mancuso Daniele Orsucci Corrado Angelini Enrico Bertini Valerio Carelli Giacomo Pietro Comi Maria Alice Donati Antonio Federico Carlo Minetti Maurizio Moggio Tiziana Mongini Filippo Maria Santorelli Serenella Servidei Paola Tonin Antonio Toscano Claudio Bruno Luca Bello Elena Caldarazzo Ienco Elena Cardaioli Michela Catteruccia Paola Da Pozzo Massimiliano Filosto Costanza Lamperti Isabella Moroni Olimpia Musumeci Elena Pegoraro Dario Ronchi Donato Sauchelli Mauro Scarpelli Monica Sciacco Maria Lucia Valentino Liliana Vercelli Massimo Zeviani Gabriele Siciliano 《Journal of neurology》2015,262(5):1301-1309
100.